Upload
researchonglobalmarketscom
View
214
Download
0
Embed Size (px)
Citation preview
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 1/12
Healthcare Sector in India
Monthly Update
December 2012
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 2/12
Healthcare Sector – Monthly Update
Top Story
CSTM to initiate stem cell course
The Calcutta School of Tropical Medicine (CSTM) has decided to initiate a fellowship coursein stem cell biology that happens to be the 1st ever in India. The post‐graduate programme —
Regeneration Medicine and Translational Science has already received consent from the
West Bengal State Health Department. The course will be offered to students who have
completed their MBBS degree course for which 20 such students have already been
shortlisted for 2013 1st batch.
The course that CSTM will commence shortly is available currently only in reputed
universities such as Translational Centre for Regenerative Medicine in Germany and
University of Liverpool and Stanford University. The course is aimed at teaching how dead
tissues of brain, kidney could be used in various purposes for clinical research. The
programme will help push forth Indis’s position in stem cell therapy a step ahead.
News Update
General
Venus to conduct final stage clinical trial of NCE VRP1620
Venus Remedies Ltd. has acquired the approval to conduct phase III clinical trial of cancer
detecting New Chemical Entity (NCE) from the Drugs Controller General of India (DCGI). The
phase III clinical trial for the early cancer detection molecule VRP1620 will involve aninvestment of approximately INR 55 mn.
Venus is in plans to launch the NCE by the end of calendar year 2013 in domestic and
international market. Presently, across the globe there is no technology for early detection of
small‐sized solid tumours. With expected launch of the product that the company claims to
keep at an affordable price there will be a major breakthrough in oncology therapeutic
branch.
UK government keen on upgrading Indian primary healthcare
The UK government is in plans of partnering with India’s primary healthcare segment. It is
working towards partnerships with such primary healthcare segments with the intention of uplifting their treatment standards. UK government has already initiated a pilot project in
partnership with Kerala government for upgrading 3 government‐run primary healthcare
centres of the Thiruvananthapuram district.
The partnerships can take place through public private partnerships (PPPs) and also at the
private level where business houses and corporate entities can venture into collaborations
with UK hospitals and General Practitioner (GP) networks.
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 3/12
Healthcare Sector – Monthly Update
Glenmark ties up with Forest Laboratories
Glenmark Pharmaceuticals SA (GPSA) has signed a pact with US based Forest Laboratories
Inc. for drug molecules development for treatment of chronic inflammation. Glenmark has
already identified clinical candidates and is conducting pre‐clinical studies and otherdevelopment activities required to support initiation of first‐in‐human dosing.
As per the agreement, Glenmark will receive INR 500 mn in part payment from Forest
Laboratories for development of mPGES‐1 inhibitors that will treat chronic inflammation
including pain. A part of the payment will be made upfront while the remaining will be made
to support the next phase of work.
Aurobindo Pharma to launch Ondansetron injections
Hyderabad based Aurobindo Pharma Ltd. has received has obtained final approval from US
Food & Drug Administration (USFDA) for manufacture and marketing of Ondansetron
injections. The injection is for the prevention of nausea and vomiting associated with initialand repeat courses of emetogenic cancer chemotherapy or postoperative nausea and/or
vomiting.
The Ondansetron injection will be available in USP 2rng/mL packaged in 40mg/20mL
multiple‐dose vials and USP 2mg/mL packaged in 4mg/2mL single‐dose vials. The product is
already ready for launch in US market.
News Update
Regulatory
Formal decision on drug pricing released
The Indian government has made its final decision of enforcing the new policy that will bring
more generic medicines under price control. The policy will extend price restrictions to 348
"essential" drugs inclusive of cancer and HIV unlike the previous policy that covered barely
74 drug compounds and their combinations. The policy will put a ceiling on the maximum
price of a drug on the basis of average price of all medicines in that category which have a
market share of at least 1%.
India’s cabinet has already approved the policy in late Nov 2012 and will be put to operationsoon. The policy will also embrace imported drugs that are on the "essential" medicines list
and this will ensure not only domestically manufactured but also imported drugs to be
accessible for common man.
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 4/12
Healthcare Sector – Monthly Update
Elder inks deal with Holding PharmaEco
Elder Pharmaceuticals Ltd. has entered into an agreement with Russia based Holding
PharmaEco for bilateral co‐operation in healthcare sector. The agreement is part of the 13 th
Annual Indo‐Russian bilateral summit.
India has already earned a good reputation of being a reliable supplier of quality drugs to
Russia. With Russian Government’s Pharma 2020 Programme, Indian pharma companies are
increasingly showing interest in collaborating with Russian partners. The respective
governments of the 2 countries are jointly working towards liberalizing registration
procedure of new drugs to boost bilateral pharma trading activities.
News Update
Expansion Plans
Eli Lily and Strides partner to market oncology drugs
USA based Eli Lilly and Co. and Bangalore based Strides Arcolab has entered into a joint
venture for increasing marketing of oncology products in emerging markets. According to
the agreement Eli Lilly will in‐license a portfolio of branded generic injectible and oral cancer
medicines manufactured by Agila Specialties, the specialties division of Strides Arcolab Ltd.
The deal which had been signed on 5th Dec, 2012 will come into effect from second half of
2013. The deal will sufficiently aid both the companies to capture a greater share of the
market due to their predefined responsibilities.
Defiance Technologies penetrates healthcare sector
Chennai based Defiance Technologies Ltd., the Hinduja Group Company, is venturing into
medical equipment manufacturing – the latest addition to its business of engineering and IT
services for automobile and defence sectors. The company has entered into partnership with
a US‐based R&D company that will aid the firm in re‐designing equipments specifically suited
for the price‐sensitive Indian market.
To understand the Indian medical equipment market that believes in refurbishing
equipments, Defiance has also tied up with two hospitals in Chennai and Bangalore. It also
has plans of entering into such a partnership with its group hospital Hinduja Hospital.Defiance’s business plan is expected to re‐model the Indian healthcare sector that is filled
with low standard refurbished equipments often hampering quality of diagnosis and
treatment for common man.
Claris enters JV with Japanese drug maker Otsuka Pharma & Mitsui
Ahmedabad based Claris Lifesciences Ltd. has entered into a joint venture (JV) with Japan
based pharmaceutical company Otsuka Pharmaceutical and Mitsui & Co Ltd. that has been
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 5/12
Healthcare Sector – Monthly Update
named Claris‐Otsuka. The agreement is worth INR 13.13 bn for which Claris will receive INR
10.50 bn over multiple agreements. Shareholding pattern will see Claris owning 20%, Otsuka
Pharma 60% and Mitsui 20%.
As according to the deal, Claris will be responsible for transfer of Common Solutions, Anti‐
Infectives, Plasma Volume Expanders and Parenteral Nutrition therapies business for India
and other emerging markets to Claris‐Otsuka. Claris will also be transferring 2 out of its 5
plants to Claris‐Otsuka. The partnership is a valuable one for Claris as it involves infusions
business expert Otsuka and global trading and financial expertise Mitsui.
Industry Expert Speak
UK government
keen
on
upgrading
Indian
primary
healthcare
– Mike
Nithavrianakis,
British deputy high commissioner in Chennai and ex -officio president of Indo-British
health initiative (IBHI)
“The collaboration can happen in different levels. The state governments can partner with
British entities to upgrade the existing primary health centers (PHCs). Further, there could
be public‐private‐partnerships in primary health care. In the private sector, family‐run
businesses or corporate entities that are keen to enter healthcare can also consider joint
venture partnerships with UK hospitals and GP networks”
Eli Lily and Strides partner to market oncology drugs - Jacques Tapiero, Eli Lilly Senior
Vice President
and
President
of
Eli
Lilly
emerging
markets
division
“The demand for high‐quality cancer medicines is unmet in many markets around the world.
This agreement will help Eli Lilly expand its portfolio and deliver high‐quality cancer
medicines to patients across emerging markets.”
Formal decision on drug pricing released - Manoj Garg, Pharmaceuticals Analyst at
Mumbai -based brokerage Edelweiss Securities Ltd.
"On a broad level, local drug makers will have to cut prices by 20%‐25% across portfolios,
while multinational drug companies will have to reduce rates by between 30% and 50%,"
Glenmark ties up with Forest Laboratories – Glenn Saldanha, Glenmark
Pharmaceuticals Chairman and Managing Director
"This collaboration reinforces our strategy of partnering to achieve our goal of launching
innovative technologies around the world.”
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 6/12
Healthcare Sector – Monthly Update
Transaction Detail (Oct – Dec 2012)
Date Buyer Target Deal Size
(INR mn)
% stake Deal Status Type
of
Transaction
17th Dec2012
Bupa AustraliaHealth Pty Ltd.
DentalCorporation
Holdings Ltd
11276 64% Planned M&A
17th Dec2012
CaracoPharmaceutical
URL PharmaN.A. N.A. Planned M&A
15th Dec2012
ErbaDiagnostics
US arm of Transasia
Bio‐MedicalsLtd.
Drew ScientificInc and JAS
Diagnostics Inc,from
Escalon MedicalCorp
N.A. N.A. Completed M&A
11th Dec2012
SutherlandGlobal Services
Apollo Health
Street (AHS)
10000 100% Planned M&A
4th Dec2012
DecisionResources
Group (DRG)Subsidiary of
PiramalEnterprises
AbacusInternational
N.A. N.A. Completed M&A
4th Dec
2012
Matrix Partners
India
Enhance
Aesthetic andCosmetic Studio
Pvt. Ltd.
N.A. N.A. Completed M&A
26th Nov
2012
TrivitronHealthcare Pvt.
Ltd.
Ani Labsystems
Ltd.1221.12 N.A. Completed M&A
22nd Nov
2012IncuCapital
Navigene Genetic
Science Pvt. Ltd.N.A. N.A. Completed Private Equity
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 7/12
Healthcare Sector – Monthly Update
21st Nov2012
Cipla Ltd.Cipla Medpro
South Africa Ltd.12101.2 51% Completed M&A
8th Nov2012
Sun PharmaIndustries Ltd.
DUSA
Pharmaceuticals,Inc.
12.65 N.A. Planned M&A
31st Oct 2012
GE EquityInternational
Mauritius
SyngeneInternational
(Biocon Ltd.subsidiary)
1250 7.69 Completed Private Equity
25th Oct
2012
Fidelity India
Capital
Trivitron
Healthcare
4000 35‐40 Planned Private Equity
22nd Oct 2012
Dr. Reddy'sLaboratories
OctoPlus N.V. 1930 100 Planned M&A
17th Oct
2012
Mylan
Laboratories
SMS
Pharmaceuticals’Vishakhapatnam
located
manufacturing
1730 N.A. Completed Acquisition
Annual Financial Results – Revenue (INR mn) – Major Healthcare
Companies Companies FY ’09 FY ’10 FY ’11 FY’ 12
Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0
Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5
Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7
Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0
Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 8/12
Healthcare Sector – Monthly Update
Dr. Reddy’s Laboratories
(DRL)69,441.00 70,277.00 74,693.00 96,737.4
GlaxosmithKlineConsumer Healthcare
Ltd.
19,757.6 23,693.3 27,688.6 28,857.3
Glenmark
Pharmaceuticals Ltd.21,241.20 25,291.30 29,490.70 40,206.4
Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5
Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1
Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0
Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543
Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3
Ranbaxy LaboratoriesLtd.
75,970.40 89,607.70 101,614.1 117,153.2
Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9
Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1
Sun PharmaceuticalsIndustries Ltd.
42,723.00 38,086.30 57,214.30 80,056.6
Torrent PharmaceuticalsLtd.
16,306.60 19,160.40 22,264.80 26,959.2
Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0
Annual Financial Results – Income (INR mn) - Major Healthcare
Companies
Companies FY ’09 FY ’10 FY ’11 FY’ 12
Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0
Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0
Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9
Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 9/12
Healthcare Sector – Monthly Update
Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0
Dr. Reddy’s Laboratories
(DRL) ‐5,168.00 1,068.00 11,040.00 14,262.1
GlaxoSmithKline Consumer
Healthcare Ltd.2,327.8 2,998.5 3,552.1 3,765.6
Glenmark PharmaceuticalsLtd.
1,916.60 3,244.70 4,532.10 4,603.5
Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6
Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5
Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7
Opto Circuits (India) Ltd. 2,087.3 2,603.0 3,672.5 5,718.8
Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0
Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5
Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6
Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4
Sun Pharmaceuticals
Industries Ltd.18,177.30 13,510.80 18,160.60 25,872.5
Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4
Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 10/12
Healthcare Sector – Monthly Update
Quarterly Financial Results – Revenue (INR mn) – Major Healthcare
Companies Companies
Oct -Dec
2011
Jan-Mar
2012
Apr-Jun
2012
Jul-Sep
2012
Biocon Ltd. 5,171.90 5,892.2 5,770.0 5,924.0
Blue Star Ltd. 5,896.9 N.A. N.A. N.A.
Cadila Healthcare Ltd. 13,524.60 14,633.9 15,161.0 15,125.0
Cipla Ltd. 17,580.00 N.A N.A. N.A.
Dabur India Ltd. 14,526.80 13,858.3 14,620.0 15,226.0
Dr. Reddy’s Laboratories
(DRL)27,692.00 26,584.0 25,406.0 28,808.5
GlaxoSmithKline ConsumerHealthcare Ltd.
6,854.0 8,608.7 7,869.6 8,275.4
Glenmark Pharmaceuticals
Ltd.10,310.90 10,751.2 10,404.1 12,551.9
Jubilant life Sciences Ltd. 10,871.70 12,235.9 12,358.9 12,197.3
Lupin Ltd. 17,917.0 20,063.7 22,191.5 22,392.6
Nestle India Ltd. 19,633.2 20,558.7 19,865.8 21,155.9
Opto Circuits (India) Ltd. 6,112.9 6,627.0 7,150.6 6,070.1
Piramal Enterprises Ltd. 5,518.30 8,858.0 7,102.9 8,285.8
Ranbaxy Laboratories Ltd. 37,923.1 36,954.0 31,740.6 26,513.9
Siemens India Ltd. 30,458.2 37601.432 33,082.4 32,693.6
Strides Arcolab Ltd. 6,864.7 5,274.7 5,082.9 5,773.4
Sun PharmaceuticalsIndustries Ltd. 21,451.30 23,299.3 26,581.4 26,572.4
Torrent Pharmaceuticals Ltd. 6,965.9 6,686.8 7,356.0 7,471.7
Wockhardt Ltd. 12,086.70 12,413.90 14,258.2 13,474.4
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 11/12
Healthcare Sector – Monthly Update
Companies
Oct -Dec
2011
Jan-Mar
2012
Apr-Jun
2012
Jul-Sep
2012
Biocon Ltd. 848.50 978.0 790.0 896.5
Blue Star Ltd. (327.6) N.A. N.A. N.A.
Cadila Healthcare Ltd. 1,492.10 1,708.8 1,947.9 951.4
Cipla Ltd. 2,699.10 N.A. N.A. N.A.
Dabur India Ltd. 1,728.20 1,705.1 1,494.0 2,023.7
Dr. Reddy’s Laboratories
(DRL)5,130.0 3,427.0 3,360.0 4,074.4
GlaxoSmithKline ConsumerHealthcare Ltd.
591.0 1,319.7 1,066.0 1,285.5
Glenmark Pharmaceuticals
Ltd.461.20 1,482.7 782.8 1,567.5
Jubilant life Sciences Ltd. ‐783.90 ‐635.3 50.1 1,520.0
Lupin Ltd. 2,350.60 1,556.4 2,803.9 2,904.6
Nestle India 2,308.30 2,757.3 2,459.7 2,673.1
Opto Circuits (India) Ltd. 1,250.8 2,093.5 1,380.2 1,162.4
Piramal Enterprises Ltd. 85.2 ‐386.8 40.8 (920.2)
Ranbaxy Laboratories Ltd. ‐29,827.7 12,467.6 ‐5,857.3 7,541.7
Siemens India Ltd. 1,873.6 3,040.0 (157.8) (557.7)
Strides Arcolab Ltd 684.1 6,420.7 904.8 524.9
Sun Pharmaceuticals
Industries Ltd.6,683.0 8202.1 7,955.5 3,196.4
Torrent Pharmaceuticals Ltd 831.8 ‐16.5 1,018.5 1,072.5
Wockhardt Ltd. 2,128.10 ‐1,916.4 3,779.7 4,535.5
* denotes a change in financial year
Quarterly Financial Results – Income (INR mn) - Major Healthcare
Com anies
7/29/2019 Healthcare Sector in India Monthly Update December 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 12/12
Healthcare Sector – Monthly Update
Events Calendar
Research on India (ROI) is a leading source for market research on various sectors in India
that offers premium research content from worldwide publishers of market research
reports.
Contact us:
W: https://www.researchonindia.com
T: India (Toll Free): 1800 102 1133; International: +91 (33) 4027 6214/5
Connect with
Us
Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.
International Conference on Diabetes and its
Complications
Date: 18th ‐20th Jan 2013
Venue: CHARUSAT Conference Hall, P D PatelInstitute of Applied Sciences Changa, Dist.
Anand, Gujarat Organizer: Charusat Healthcare and Research
Foundation & Charotar University of Science and Technology
Website: www.charusat.ac.in/icdc‐2013/ Contact Person: Dr. Aditi BuchContact No.: +91 9825592847E-mail: [email protected]
Global Healthcare Summit
Date: 1st – 3rd
Jan, 2013 Venue: International Convention Centre, CochinOrganizer: American Association of Physicians of
Indian OriginWebsite: www.aapighsindia.org/ghcs_abt_main.php E- mail: [email protected] and